RespireRx Pharmaceuticals Inc. (RSPI) – Press Releases
-
ResolutionRx Ltd, a Subsidiary of RespireRx Pharmaceuticals Inc., Enters into Letter of Intent with Cantheon Capital for the Financing of Anticipated Research and Development Costs
-
RespireRx Pharmaceuticals Inc. Establishes Research Collaboration With University College London to Study the Use of AMPAkines for the Treatment of GRIA Disorders
-
RespireRx Pharmaceuticals Inc. Discloses Novel Structural Analogs of its GABAA Receptor Potentiator, KRM-II-81 with Antiseizure Efficacy and Antitremor Effects without Sedation.
-
RespireRx Pharmaceuticals Inc. Announces the Appointment Joseph Siegelbaum as an Independent Member of the Board of Directors
-
ResolutionRx Ltd and RespireRx Pharmaceuticals Inc. Announce ResolutionRx’s Entry into a Services Agreement with iNGENu CRO Pty Ltd
-
ResolutionRx Ltd, a wholly owned subsidiary of RespireRx Pharmaceuticals Inc. Enters into LOI and Term Sheet with Radium Capital for the financing of anticipated Research and Development Credits
-
RespireRx Pharmaceuticals Inc. Announces the 2nd Amendment to its License Agreement with the University of Illinois
-
RespireRx Pharmaceuticals Inc. Establishes ResolutionRx Ltd in Australia to Develop Its Pharmaceutical Cannabinoid Platform
-
RespireRx Pharmaceuticals Inc. Enters a Collaboration With National Institute for Neurological Disorders and Stroke to Advance its Lead GABAkine Toward Clinical Development
-
RespireRx Pharmaceuticals Inc. Announces Entry into Letter of Intent with Australian Headquartered CRO for Dronabinol Development for Obstructive Sleep Apnea
-
RespireRx Pharmaceuticals Inc. Announces that Jeff Margolis, the Company’s CFO is presenting at the Investor Summit Q4
-
RespireRx Pharmaceuticals Inc. Announces that Dr. Arnold Lippa Is an Invited Speaker at the 5th Meridian Drug Discovery Summit
-
RespireRx Pharmaceuticals Inc. Announces that Sleep Review has discussed the RespireRx Dronabinol Obstructive Sleep Apnea (OSA) Program in its June 13, 2022 Edition
-
RespireRx Pharmaceuticals Inc. Announces that Dr. Arnold Lippa is an Invited Speaker at the 5th International Cannabinoid-Derived Pharmaceuticals Summit
-
RespireRx Pharmaceuticals Inc. Announces Recent RespireRx Presentation at 2022 GRI Virtual Conference presented by CureGRIN and GRIN Therapeutics.
-
RespireRx Pharmaceuticals Inc. Announces the Publication of a Review Article Highlighting the Potential Use of GABAkine Neuromodulators for the Treatment of Tinnitus
-
RespireRx Pharmaceuticals Inc. Announces Patent Filings Claiming Novel Lipid Based Formulations for Insoluble Compounds, Including Cannabinoids Such as Dronabinol
-
RespireRx Pharmaceuticals Inc. Announces Discovery of a New GABAkine Neuromodulator that Protects Against Seizures and Lethality
-
Letter to Stockholders and Other Stakeholders: A Brief Summary of Our Progress During Past Twelve Months and a Peek Looking Forward
-
RespireRx Pharmaceuticals Inc. Announces Publication of a Manuscript Describing Its Newest Neuromodulator for Pharmacoresistant Epilepsy and Chronic Pain
-
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
-
RespireRx Pharmaceuticals Inc. to Present at Upcoming Virtual Life Sciences Investor Conference and Biotech Showcase™
-
Life Sciences Virtual Investor Conference: Company Executives Present Live December 16th
-
RespireRx Pharmaceuticals Inc. Announces Publication of Review Article Describing Advances in the Discovery, Development and Commercialization of GABAkines, Including KRM-II-81
-
RespireRx Pharmaceuticals Inc. Announces Publication of Book Chapter Describing Novel Analgesic Properties of KRM-II-81
-
RespireRx Pharmaceuticals Inc. Announces Publication of Preclinical Results Supporting the Use of AMPAkines in the Treatment of Human Spinal Cord Injury
-
RespireRx Pharmaceuticals Inc. Announces CEO’s OTC Venture Market Podcast
-
RespireRx Pharmaceuticals Inc. Announces Video Interview of CFO
-
RespireRx Pharmaceuticals Inc. to Present in June 2021 Access China Biotech Virtual Investor Conference
-
RespireRx Pharmaceuticals Inc. Announces New Data Regarding the Use of AMPAkines as Potential Treatments for Spinal Cord Injury
-
RespireRx Pharmaceuticals Inc. Provides Update on Its Development Programs
-
Corrected Headline: RespireRx Pharmaceuticals Up Listed to OTCQB and Ticker Returns to RSPI
-
RespireRx Pharmaceuticals Inc. Announces 10 to 1 Reverse Stock Split
-
RespireRx Pharmaceuticals Inc. to Participate in Upcoming January Virtual Investor Conferences
-
RespireRx Pharmaceuticals Inc. Announces 10 to 1 Reverse Stock Split
-
RespireRx Pharmaceuticals Inc. Announces Appointment of Dr. James Cook and Dr. Jeffrey Witkin as Research Fellows
-
RespireRx Pharmaceuticals Inc. Announces Publication of Preclinical Results Supporting the Use of Ampakines in the Treatment of Spinal Cord Injury
-
RespireRx Pharmaceuticals Inc. Announces Appointment of David Dickason as Senior Vice President Pre-Clinical Product Development
-
RespireRx Pharmaceuticals Inc. Announces $2 Million Funding Commitment Allowing Option Exercise with UWM Research Foundation, Inc. and Entry into a License Agreement for GABA(A) Receptor Allosteric Ne
-
RespireRx Pharmaceuticals Inc. Announces Extension to Long-Term Employment Contract with Tim Jones as President and Chief Executive Officer
-
RespireRx Pharmaceuticals Inc. Announces Appointment of Timothy Jones as President and Chief Executive Officer
-
RespireRx Pharmaceuticals Inc. Announces Entry into Option Agreement to License GABA(A) Receptor Allosteric Neuromodulator Intellectual Property from the UWM Research Foundation, Inc.
-
RespireRx Pharmaceuticals Inc. CEO Issues Progress and Status Report
-
RespireRx Pharmaceuticals Inc. Announces the Filing of Broad Enabling Cannabinoid Continuation-in-Part and New Provisional Patent Applications
-
RespireRx Pharmaceuticals Inc. Announces the Filing of Broad Enabling Cannabinoid Continuation-in-Part and New Provisional Patent Applications
-
RespireRx Pharmaceuticals Inc. Announces Appointment of Tim Jones to its Board of Directors
-
RespireRx Pharmaceuticals Inc. Announces Appointment of Tim Jones to its Board of Directors
-
RespireRx Pharmaceuticals Inc. Executives Participating in the 2nd Annual International Cannabinoid Derived Pharmaceuticals Summit
-
RESPIRERX PHARMACEUTICALS INC. SEND NOTICE LETTER TO THE BOARD OF DIRECTORS OF THERAPIX BIOSCIENCES LTD.
-
RespireRx Pharmaceuticals Inc. and Impression Healthcare Limited Announce Agreement to Explore Commercialization of Dronabinol for the Treatment of Obstructive Sleep Apnea (OSA) in Australia, New Zeal
Back to RSPI Stock Lookup
